GT307 TIL Injection Clinical Trial for Metastatic Solid Tumors

NIH ClinicalTrials.gov registered a new clinical trial (NCT07534813) for GT307, an investigational autologous tumor-infiltrating lymphocyte (TIL) injection developed for the treatment of metastatic and recurrent advanced solid tumors. The single-arm, open-label study will evaluate safety, tolerability, pharmacokinetic profile, and efficacy to determine optimal dosage regimens in patients with advanced solid tumors.

For compliance officers tracking oncology drug pipelines, this trial registration provides visibility into upcoming cellular therapy research for solid tumor indications. While this registry entry creates no compliance obligations, organizations involved in TIL therapy development or treating relevant patient populations should monitor trial progress for potential competitive or clinical developments.